Quantcast
Home > Quotes > ENOB

Enochian Biosciences, Inc. Common Stock (ENOB) Quote & Summary Data

ENOB 
$6.5
*  
0.48
6.88%
Get ENOB Alerts
*Delayed - data as of Dec. 13, 2018  -  Find a broker to begin trading ENOB now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ENOB Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 7 / $ 6.50
Share Volume
20,948
50 Day Avg. Daily Volume
N/A
Previous Close
$ 6.98
52 Week High / Low
$ 9 / $ 6.50
Market Cap
235,130,506
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
20,948
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $6.50 Equals the 52 week low.

Intraday Last 52 Weeks
High: $ 7 $ 9
 Low: $ 6.50 $ 6.50

Company Description (as filed with the SEC)

Enochian BioSciences, Inc. is a biopharmaceutical company dedicated to identifying, developing, manufacturing and commercializing gene therapies. We accomplish this by translating groundbreaking science combined with our expertise in gene therapy, gene regulation and cell therapy. Our gene therapy platform can be applied to multiple indications. We are first applying our technology to develop therapies seeking to improve the lives of patients with HIV/AIDS through the restorative potential of gene therapy. Additionally, we have combined the gene therapy platform with our extensive knowledge of dendritic cells to develop a novel proprietary immuno-oncology technology platform. In the process of developing our HIV/AIDS and oncology platforms, we are accruing significant scientific, manufacturing and regulatory capabilities as well as building upon our proprietary knowledge that is applicable in the broader field of gene therapy.  ... More ...  

Nasdaq Official Price

Open Price:
$ 7
Open Date:
Dec. 13, 2018
Close Price:
$ 6.23
Close Date:
Dec. 13, 2018

Research Brokers before you trade

Want to trade FX?

Analyst Info